medigraphic.com
ISSN 2007-4360 (Print)
Asociación Mexicana de Periodontología, Colegio de Periodoncistas A.C

2012, Number 1

<< Back Next >>

Rev Mex Periodontol 2012; 3 (1)

Interdisciplinary dental treatment in a patient with thyroid disorders. A case report

Ruiz GAC, Soto CAA, Yerena BBL, Robles GC, Martínez RVMC

Language: Spanish
References: 39
Page: 30-37
PDF size: 205.03 Kb.


ABSTRACT

Background: The comprehensive medical care requires an interdisciplinary intervention, when the physician performs the initial assessment and establishing the diagnosis of a patient, it is important not to overlook oral manifestations that might occur. These manifestations may be primary, which may help establish the diagnosis; we also find oral manifestations secondary as a result of previous medical treatments or as indicators of the degree of systemic deterioration of the patient. Early diagnosis of such events helps the patient’s medical treatment. Procedures: In this case report, the objective was to interdisciplinary dental diagnosis and treatment of a patient with thyroid disorders. Through medical history, consultation with the medical and dental specialties different established the following Results: His initial diagnosis was Grave’s disease at 25 years old, initially treated with drug therapy (carbimazole) and subsequently with radioactive iodine, now you have hypothyroidism, which is treated with levothyroxine for life. At present oral mild chronic periodontitis and generalized caries. Conclusions: An adequate knowledge of disease and its relationship to the oral cavity allows a more complete understanding between oral health and general health. The management of patients with systemic diseases, whose treatment requires the use of therapies that promote an underlying disease, requires close collaboration between health professionals. Likewise, being able to predict and prevent drug interactions is important to optimize the pharmacological responses of drugs and minimize the risk of adverse or toxic reactions thereof. It is the job of doctors and dentists make early diagnosis, timely and effective precisely to channel patients to specialists, in order to give people a bigger picture of interdisciplinary care. Proper diagnosis is essential for a successful outcome.


REFERENCES

  1. Philippe J. Grave’s disease in 2009. Rev Med Suisse 2009; 5 (198): 764-768.

  2. Horacek J, Franklyn J. A: Radioiodine treatment of Grave’s hyperthyroidism. J Clin Endocrinol Metab 2003; 88: 6113.

  3. Weetman A. Grave’s disease. N Engl J Med 2000; 343: 1236-1248.

  4. Cooper D. Hyperthyroidism. Lancet 2003; 362: 459-468.

  5. Lind P. Strategies of radioiodine therapy for Grave’s disease. Eur J Nucl Med Mol Imaging 2002; 29 (2): 453-457.

  6. Schlumberger M. Papillary and follicular thyroid carcinoma. N Engl J Med 1998; 338: 297-306.

  7. Vini L, Harmer C. Management of thyroid cancer. Lancet Oncol 2002; 3: 407-414.

  8. Markitziu A, Lustmann J. Salivary and lacrimalgland involvement in a patient who had undergone a thyroidectomy and was treated with radioiodine for thyroid cancer. Oral Surg Oral Med Oral Pathol 1993; 75: 318-322.

  9. Alexander C, Bader J. Intermediate and long-term side effects of high dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39: 1551-1554.

  10. Lin W, Shen Y, Wang J. Short term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 1996; 21: 780-782.

  11. Malpani L, Samuel M, Ray S. Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol 1996; 35: 535-540.

  12. Bohuslavizki K, Brenner W, Lasmann S et al. Quantitative salivary glandscintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Nucl Med Commun 1996; 17: 681- 686.

  13. Stephens L, Schultheiss T et al. Radiation apoptosis of serous acinar cells of salivary and lacrimal glands. Cancer 1991; 67: 1539-1543.

  14. Dohan O, De la Vieja A et al. The sodium/iodidsymporter (NIS): characterization, regulation and medical significance. Endocr Rev 2003; 24: 48-77.

  15. Kolbert K, Pentlow K et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med 2007; 48: 143-149.

  16. Alexander C, Bader J et al. Intermediate and long term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998; 39: 1551-1554.

  17. Nakada K, Ishibashi T, Takei T et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005; 46: 261-266.

  18. Solans R, Bosch J et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 2001; 42: 738-743.

  19. Bohuslavizki K, Klutmann S, Brenner W et al. Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol 1998; 16: 3542-3549.

  20. Maier H, Bihl H. Effect of radioactive iodine therapy on parotid gland function. Acta Otolaryngol 1987; 103: 318-324.

  21. Kielbassa A, Hinkelbein W et al. Radiation-related damage to dentition. Lancet Oncol 2006; 7: 326-335.

  22. Stone H, Coleman C et al. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 2003; 4: 529-536.

  23. Hashimi I. The management of Sjögren’s syndrome indental practice. J Am Dent Assoc 2001; 132: 1409-1417.

  24. Thylstrup A, Fejerskov O. Cardiologia Clínica. São Paulo: Santos; 2001.

  25. Mandel S, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003; 13: 265-271.

  26. Keats A. The ASA classification of physical status-a recapitulation. Anesthesiology 1978; 49 (4): 233-236.

  27. Armitage G. Development of a classification system for periodontal conditions. The American Academy of Periodontology 1999; 4 (1): 1-6.

  28. Pumarola J, Canalda C. Patología de la pulpa y del periápice. Cap. 6. Endodoncia. Madrid Masson; 2001.

  29. Levine R, Hill F. Rampant caries and its management: Part 1; Clinical manifestations and aetiology. Br Dent J 1978; 145: 210-212.

  30. McGuire M, Nunn M. Prognosis versus actual outcome. II. The effectiveness of clinical parameters in developing an accurate prognosis. J Periodontol 1996; (67): 658-665.

  31. Canadas V, Vilar L, Moura E et al. Evaluation ofradioiodine therapy with fixed doses of 10 and 15 mCi in patients with Grave’s disease. Arq Bras Endocrinol Metabol 2007, 51: 1031-1033.

  32. Hernández S, Pachón A et al. Radioiodine treatment in autoimmune hyperthyroidism: analysis of outcomes in relation to dosage. Arch Med Res 2007; 38: 185-189.

  33. Brown A, Greening W et al. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984; 57: 323-327.

  34. Bohuslavizki K, Brenner W, Lasmann S et al. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine. Nucl Med Commun 1996; 17: 681- 686.

  35. Bohuslavizki K, Brenner W, Lassmann S et al. Quantitative salivary gland scintigraphy: a recommended examination prior to and after radioiodine therapy [in German]. Nuklearmedizin 1997; 36: 103-109.

  36. Allweiss P, Braunstein G, Katz A, Axman A. Sialadenitis following I-131 therapy for thyroid carcinoma. J Nucl Med 1984; 25: 755-758.

  37. DiRusso G, Kern K. Comparative analysis of complications from I-131 radioablation for well-differentiated thyroid cancer. Surgery 1994; 116: 1024-1130.

  38. Hart G, Moinous E. The treatment of radiation necrosis with hyperbaric oxygen. Cancer 1976; 37: 2580.

  39. Pantos C, Mourouzis I, Xinaris C, Cokkinos D. Thyroid hormone and myocardial ischaemia. J Steroid Biochem Mol Biol 2008; 109 (3-5): 314-322.




2020     |     www.medigraphic.com